1 Ağustos 2026, Cumartesi · 00:51 Piyasalar Kapalı
borsapanel.com Borsanın nabzı, tek panelde.
Abone Ol

Labcorp raises annual profit forecast on strong testing demand

Labcorp raises annual profit forecast on strong testing demand

The logo for Labcorp, Laboratory Corporation of America, a life sciences company is displayed on a screen on the floor of the New York Stock Exchange (NYSE) in New York City, U.S., June 22, 2023. REUTERS/Brendan McDermid · Reuters
By Sahil Pandey

Thu, July 30, 2026 at 3:26 PM GMT+3 2 min read

By Sahil Pandey

July 30 (Reuters) - Laboratory operator Labcorp raised its annual profit forecast and posted better-than-expected second-quarter results on Thursday, ‌as steady demand for diagnostic testing and growth in ‌its drug-development services business boosted performance.

Shares of the company fell about 6% in ​premarket trading.

Here are more details:

• The company's diagnostics business has benefited from specialty testing and laboratory management agreements, while improved pharmaceutical and biotechnology spending has supported its research services business.

• Leerink Partners ‌analyst Michael Cherny said ⁠investors were likely focused on softer-than-expected organic growth in Labcorp's Diagnostics Laboratories segment after rival Quest ⁠Diagnostics set a higher bar with last week's results.

• Revenue at Labcorp's Diagnostics Laboratories segment grew 5.5% to $2.90 billion, slightly below analysts' ​expectation of $2.91 ​billion.

• Peer Quest Diagnostics last ​week raised its full-year ‌profit forecast after demand for routine diagnostic testing helped the company beat second-quarter estimates.

• Labcorp raised its 2026 adjusted earnings forecast to $18.10 to $18.55 per share from $17.70 to $18.35 previously.

• The midpoint of the new range, $18.33, is above analysts' estimate of $18.01 per share, according ‌to data compiled by LSEG.

• The ​company lifted its annual revenue forecast ​to a range of $14.71 ​billion to $14.83 billion from its previous projection of $14.65 ‌billion to $14.80 billion. Analysts expect revenue ​of $14.71 billion.

• ​Revenue at its Biopharma Laboratory Services segment rose 6.5% to $836.2 million, exceeding estimates of $797.3 million.

• Overall second-quarter revenue rose ​5.8% to $3.73 billion, above ‌estimates of $3.71 billion. Adjusted earnings per share of $4.99 topped ​expectations of $4.78.

(Reporting by Sahil Pandey in Bengaluru; Editing by ​Tasim Zahid and Diti Pujara)

Kaynak: Yahoo Finance
İlgili Haberler
Global Investors may want to focus on front end of yield curve — as Street anticipates next Fed meetings CNBC Finance · 3 saat önce Global Analyst Report: PACCAR Inc Yahoo Finance · 3 saat önce Global Analyst Report: Mastercard Inc Yahoo Finance · 3 saat önce Global Analyst Report: Unilever PLC Yahoo Finance · 3 saat önce Global Analyst Report: Lam Research Corp Yahoo Finance · 3 saat önce

Yorumlar (0)

Giriş yaparak yorum yazabilirsin.

İlk yorumu sen yaz.